エピソード

  • How Long Tirzepatide Stays in Your Body (Half-Life Explained) | Mounjaro/Zepbound Guide

    How Long Tirzepatide Stays in Your Body (Half-Life Explained) | Mounjaro/Zepbound Guide
    2026/10/01
    #Tirzepatide #Mounjaro #Zepbound #GLP1 #WeightLossHow long does tirzepatide (Mounjaro, Zepbound) actually stay in your system? It's not 5 days. In this video, I explain tirzepatide's half-life using 4 clocks it sets in your body. Those clocks explain when side effects hit and what to do if you miss a dose. They also explain why a 1-week pause before surgery may not be enough, why the birth control rule is 4 weeks, and how long the drug takes to clear after your last shot.Then we get to the clock that matters most: what happens after you stop. You'll see what the SURMOUNT-4 trial found about weight regain and why muscle loss is the real risk. I'll also share how I regained 45 pounds when my own structure disappeared, and the 2 paths that protect your results.📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.comTIMESTAMPS00:00 Why "it's gone in 5 days" is wrong01:26 What tirzepatide is and how it works02:25 Half-life explained02:59 Why it lasts so long: albumin binding03:48 Clock 1: the 7-day clock04:18 Side effects: when they hit and how to ease them05:47 Why food noise returns at the end of the week06:14 Missed a dose? The 96-hour rule07:16 Clock 2: the 4-week clock and steady state08:06 Why your dose goes up in 2.5 mg steps09:05 Birth control: the 4-week rule10:09 Clock 3: how long tirzepatide stays in your system10:56 What makes clearance faster or slower12:39 Why severe side effects don't stop when you stop13:42 Surgery, colonoscopy and sedation15:07 Pregnancy planning15:35 Will it show up on a drug test?16:12 Clock 4: what happens when you stop16:46 Why your body fights weight loss17:36 SURMOUNT-4: stopping vs staying on17:58 My own weight-regain story18:48 The muscle problem19:51 The plan: 2 good paths21:17 Protecting your muscle on GLP-1sREFERENCESEli Lilly and Company. ZEPBOUND (tirzepatide) prescribing information. https://pi.lilly.com/us/zepbound-uspi.pdfKindel TL, et al. Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period. 2024. https://www.cghjournal.org/article/S1542-3565(24)00910-8/fulltextAmerican Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. June 29, 2023. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperativeAronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48. https://jamanetwork.com/journals/jama/fullarticle/2812936Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597–1604. https://pubmed.ncbi.nlm.nih.gov/22029981/Eli Lilly and Company. SURMOUNT-1 results published in The New England Journal of Medicine. 2022. https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicineDeacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004;36:761–765.Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24(8):1612–1619. https://onlinelibrary.wiley.com/doi/full/10.1002/oby.21538Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/39996356/Paika MK. GLP-1 Masterclass; The Weight Equation; Obesity Medicine in Clinical Practice: High-Yield Guide; The Physician's Physique.⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
    続きを読む 一部表示
    22 分
  • Can Ozempic & GLP-1s Make You Blind? A Doctor Explains

    Can Ozempic & GLP-1s Make You Blind? A Doctor Explains
    2026/09/29
    #Ozempic #GLP1 #Wegovy #EyeHealth #obesitymedicine Can Ozempic, Wegovy or Mounjaro make you blind? A viewer asked me this, and it deserves an honest, evidence-based answer. I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine, with more than 15 years as a hospitalist.In this video I review every major study on GLP-1 medications and NAION, a rare "stroke" of the optic nerve:The Mass Eye and Ear study that sparked the headlinesThe larger studies from Denmark, Norway and the USThe randomized trialsI also cover what the European Medicines Agency, the UK's MHRA and the American Academy of Ophthalmology concluded, plus the separate issue of diabetic retinopathy. You'll learn the real risk in actual numbers, who is at higher risk, and a 5-step eye-safety plan, including the one warning sign that means you go to the ER the same day.TIMESTAMPS0:00 Can GLP-1s make you blind? A viewer's question0:58 Who I am and why this matters1:37 What is NAION? The "stroke" of the optic nerve3:15 How the alarm started: the Mass Eye and Ear study4:16 What the bigger studies found6:13 GLP-1 Masterclass6:51 What regulators and eye specialists concluded8:44 Putting the risk in perspective9:28 The other eye issue: diabetic retinopathy10:41 Free GLP-1 Diet Cookbook11:01 Who is at higher risk?12:16 The 5-step eye-safety plan14:10 What to watch next📩 FREE GLP-1 Diet Cookbook + Weekly Newsletterhttps://www.drmohammedpaika.com/newsletter🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.comREFERENCESStatPearls: Nonarteritic anterior ischemic optic neuropathy. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK559045/Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 1994;14(1):38-44Hathaway JT, Shah M, Hathaway DB, et al. Risk of NAION in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-739Grauslund J, Abou Taha A, Molander LD, et al. Once-weekly semaglutide doubles the five-year risk of NAION in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous. 2024;10:97Simonsen E, Lund LC, Ernst MT, et al. Use of semaglutide and risk of NAION: a Danish–Norwegian cohort study. Diabetes Obes Metab. 2025;27(6):3094-3103Hsu AY, et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol. 2025. doi:10.1001/jamaophthalmol.2025.0349Wang L, Volkow ND, Kaelber DC, Xu R. Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes. JAMA Netw Open. 2025;8(8):e2526327DeParis SW, et al. GLP-1 receptor agonists and the risk of NAION: a consensus statement by NANOS and the American Academy of Ophthalmology. Ophthalmology. 2026;133(8)NAION risk with semaglutide: what we know so far (includes Chou et al., 18,657 patients). Eye. 2025. https://www.nature.com/articles/s41433-025-03833-yLiu Z, Raveendran D, Fourlanos S, et al. Rate and risk of NAION with semaglutide use for diabetes and weight loss: a systematic review and meta-analysis. Ophthalmology. 2026;133:589-598European Medicines Agency (PRAC). NAION a very rare side effect of semaglutide. June 2025. https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovyMHRA Drug Safety Update: Semaglutide and risk of NAION. Feb 5, 2026Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232Centers for Disease Control and Prevention. Diabetes and vision lossMarso SP, et al. Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844Vilsbøll T, et al. Semaglutide, reduction in HbA1c and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889-897Leinung M, Patel N, Bettadahalli S, Paika MK, et al. Benefits of short-term professional continuous glucose monitoring in clinical practice. Diabetes Technol Ther. 2013Campbell UB, et al. Acute NAION and exposure to phosphodiesterase type 5 inhibitors. J Sex Med. 2015;12(1):139-151⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
    続きを読む 一部表示
    15 分
  • You’re Missing the Biggest GLP-1 Benefit (And It’s NOT Weight Loss)

    You’re Missing the Biggest GLP-1 Benefit (And It’s NOT Weight Loss)
    2026/09/26
    #GLP1 #Ozempic #Mounjaro #Wegovy #ObesityMedicineMost people think GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound are just for weight loss. The research tells a much bigger story. I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine, with more than 15 years as a hospitalist. In this video I count down 12 evidence-graded health benefits of GLP-1 medications beyond the scale, plus a bonus from the newest cancer research.You'll learn what the major trials show about your heart, liver, kidneys, blood pressure, sleep apnea, inflammation, alcohol cravings, joint pain and blood sugar. I also cover what the latest Alzheimer's trials actually found. Stay for number 1: a major analysis of the SELECT trial found that about two-thirds of the heart protection wasn't explained by weight loss.📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.comTIMESTAMPS0:00 Why GLP-1s are about more than weight loss1:05 Who I am and why this matters1:56 #12 Blood pressure and blood fats2:42 #11 Less joint pain, more mobility3:52 #10 Fewer alcohol cravings5:00 #9 A healthier liver5:50 #8 Brain health: the honest version6:55 How to protect muscle on a GLP-1 + Masterclass8:42 #7 Sleep apnea and deeper sleep9:40 #6 Fewer medications and diabetes prevention10:35 BONUS: GLP-1s and cancer, the newest research11:38 Free GLP-1 Diet Cookbook12:03 #5 Quieter food noise and steadier blood sugar12:57 #4 Protecting your kidneys13:46 #3 Blood sugar and diabetes control14:35 #2 Cooling down inflammation15:27 #1 Protecting your heart and blood vesselsREFERENCESDeanfield J, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements (SELECT analysis). Lancet. 2025. PMID: 41138739Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure. Lancet. 2021;397:1625-1636Bliddal H, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis (STEP 9). N Engl J Med. 2024;391:1573-1583Eli Lilly. Retatrutide TRIUMPH-4 topline results (press release, Dec 11, 2025; not yet peer-reviewed). https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-averageKosiborod MN, et al. Semaglutide in HFpEF and obesity (STEP-HFpEF). N Engl J Med. 2023;389:1069-1084Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder. JAMA Psychiatry. 2025;82(4):395-405Klausen MK, et al. Once-weekly semaglutide vs placebo in alcohol use disorder and comorbid obesity. Lancet. 2026. PMID: 42070571Younossi ZM, et al. The global epidemiology of NAFLD and NASH. Hepatology. 2023;77(4):1335-1347Sanyal AJ, et al. Phase 3 trial of semaglutide in MASH (ESSENCE). N Engl J Med. 2025;392:2089-2099Wang W, et al. Semaglutide and first-time diagnosis of Alzheimer's disease in type 2 diabetes. Alzheimers Dement. 2024;20(12):8661-8672evoke and evoke+ Investigators. Oral semaglutide in early-stage symptomatic Alzheimer's disease. Lancet. 2026Lundgren JR, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined (S-LITE). N Engl J Med. 2021;384:1719-1730Heymsfield SB, Aronne LJ, et al. Bimagrumab plus semaglutide for obesity (BELIEVE). Nat Med. 2026. https://www.nature.com/articles/s41591-026-04204-0Malhotra A, et al. Tirzepatide for obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205Jastreboff AM, et al. Tirzepatide for obesity treatment and diabetes prevention (SURMOUNT-1, 3 years). N Engl J Med. 2025;392:958-971Lauby-Secretan B, et al. Body fatness and cancer — viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794-798(complete list available upon request)⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
    続きを読む 一部表示
    18 分
  • Mounjaro: Who Loses the Most Weight?

    Mounjaro: Who Loses the Most Weight?
    2026/09/24
    #Mounjaro #Tirzepatide #GLP1 #WeightLoss #obesitymedicine Why do two people on the same Mounjaro dose get completely different results? In this video, I break down a study of more than 3,000 people with type 2 diabetes from the SURPASS 1–4 trials. It looked at who is most likely to lose 15% or more of their body weight on tirzepatide (Mounjaro / Zepbound), and why.You'll learn the 7 factors that predicted the biggest weight loss. Several of them are things you can change, sometimes before your first injection. I also cover what newer research says about Ozempic and Wegovy, why real-world results are lower than trial results, and the 6-month check-in that tells you whether you're on track.📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.comTIMESTAMPS0:00 Same drug, very different results1:15 Mounjaro vs Zepbound vs Ozempic explained2:19 What the SURPASS study measured3:32 Factor 1: Sex4:36 Factor 2: Age (and muscle loss)6:32 Factor 3: Your starting blood sugar8:36 Factor 4: Your cholesterol9:32 GLP-1 Masterclass10:12 Factor 5: Your other medications11:41 Factor 6: Dose12:34 Factor 7: Race and ethnicity13:29 Surprise: starting weight didn't matter13:58 Does this apply to Ozempic and Wegovy?15:26 The limits of this research16:36 7 steps to improve your odds19:52 Free GLP-1 Diet Cookbook + what's nextREFERENCESMałecki MT, Batterham RL, Sattar N, et al. Predictors of ≥15% weight reduction and associated changes in cardiometabolic risk factors with tirzepatide in adults with type 2 diabetes in SURPASS 1–4. Diabetes Care. 2023;46(12):2292-2299. doi:10.2337/dc23-1135Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36.Aronne LJ, Horn DB, Kokkinos AD, et al. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026;139(7):913-921. doi:10.1016/j.amjmed.2026.03.010Powell W, Song X, Mohamed Y, et al. Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data. Obesity (Silver Spring). 2023;31(10):2482-2492. doi:10.1002/oby.23859Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729.Sattar N, Frühbeck G, Andreelli F, et al. Weight reduction with tirzepatide varied meaningfully by baseline HbA1c category in adults with overweight or obesity and type 2 diabetes in SURMOUNT-2. Diabetes Care. 2025;48(11):e136-e137. doi:10.2337/dc25-1442Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024.Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. Am J Clin Nutr. 2015;101(6):1320S-1329S.Mechanick JI, Butsch WS, Christensen SM, et al. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev. 2025;26(1):e13841.Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48.Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362.⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
    続きを読む 一部表示
    21 分
  • 10 Best Foods That Help Ozempic & Zepbound Work BETTER: Weight Loss Doctor Explains

    10 Best Foods That Help Ozempic & Zepbound Work BETTER: Weight Loss Doctor Explains
    2026/09/22

    #GLP1 #Ozempic #Zepbound #Wegovy #weightloss

    Losing weight on Wegovy, Ozempic, Zepbound, or Mounjaro? What you eat while you're on it matters more than most people realize. In this video, board-certified internal medicine and obesity medicine physician Dr. Mohammed Paika breaks down the 3 nutrition gaps that show up again and again in GLP-1 patients — protein, fiber, and fluids — and the 10 foods that address them, backed by real research on muscle preservation, gut health, and the GLP-1 pathway itself.

    You'll learn why eating less doesn't automatically mean eating well, what the research says about muscle loss on semaglutide and tirzepatide, and exactly which foods to prioritize so you protect your muscle, support your gut, and get more out of your medication — not just a smaller number on the scale.


    🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
    Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
    https://www.drmohammedpaika.com

    📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
    Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
    https://www.drmohammedpaika.com/newsletter

    📚 The Weight Equation & The Physician’s Physique
    Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
    https://www.drmohammedpaika.com/books

    👥 Metabolic Health Community
    https://www.skool.com/metabolic-health-community-5316
    👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
    Board-Certified in Internal Medicine and Obesity Medicine
    Certified Personal Trainer & Nutrition Coach
    Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

    Timestamps
    0:00 Intro — The Mistake That's Sabotaging Your GLP-1 Results
    2:03 Why What You Eat Matters More Than Ever
    5:17 The 3 Nutrition Gaps on GLP-1 Medications
    7:33 #1 Oats
    8:55 #2 Turkey Breast
    10:18 #3 Tofu & Edamame
    11:35 #4 Tuna & Shrimp
    12:44 #5 Quinoa
    13:49 #6 Chia Seeds & Flaxseed
    15:50 #7 Sweet Potatoes
    17:07 #8 High-Protein Milk
    18:31 #9 Kefir
    20:08 #10 Watermelon, Citrus & Coconut Water
    21:33 The One Rule That Ties It All Together
    22:06 Final Thoughts

    References

    Johnson et al. "Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study." Frontiers in Nutrition, 2025;12.
    Bikou A, et al. "A systematic review of the effect of semaglutide on lean mass: insights from clinical trials." Expert Opinion on Pharmacotherapy, 2024;25(5):611-619.
    Look M, et al. "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study." Diabetes, Obesity and Metabolism, 2025.
    Hirasawa T, et al. "Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120." Nature Medicine, 2005;11(1):90-94.
    de Jong et al. "Dietary fibers to boost endogenous GLP-1 secretion and satiety: a scoping review." Frontiers in Endocrinology, 2026.
    Tolhurst G, et al. "Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein-Coupled Receptor FFAR2." Diabetes, 2012;61(2):364-371.
    Longland TA, et al. "Higher compared with lower dietary protein during an energy deficit..." American Journal of Clinical Nutrition, 2016.
    Ogilvie AR, et al. "Higher protein intake during caloric restriction improves diet quality and attenuates loss of lean body mass." Obesity, 2022;30(11).
    Nutrition figures throughout: USDA FoodData Central.

    ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
    続きを読む 一部表示
    24 分
  • 5 Things You Should NEVER Do on Wegovy, Ozempic & Zepbound

    5 Things You Should NEVER Do on Wegovy, Ozempic & Zepbound
    2026/09/17

    #Ozempic #Wegovy #Zepbound #GLP1 #weightlossjourney

    Are you taking Wegovy, Ozempic, or Zepbound and feeling like your results have stalled? In this video, board-certified physician Dr. Mohammed Paika breaks down the 5 mistakes that quietly sabotage GLP-1 results — and exactly what to do instead to keep losing fat, protect your muscle, and avoid unnecessary side effects.

    Drawing on his experience as a hospitalist and obesity medicine specialist, Dr. Paika walks through dose titration, nutrition, digestion, and lab work — the pieces most people never get told about.

    TIMESTAMPS:
    0:00 Intro — Why Your Results Might Be Stalling
    0:53 Meet Dr. Paika
    1:37 Mistake #1: Chasing the Calendar Instead of Your Biology
    4:07 Mistake #2: Treating the Medication Like It Replaces the Basics
    6:02 Mistake #3: Eating Too Little (and Losing the Wrong Weight)
    8:29 Mistake #4: Ignoring What Your Gut Is Telling You
    10:47 Mistake #5: Never Checking Your Blood Work
    12:27 Final Thoughts + What to Watch Next

    REFERENCES:
    1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002.
    2. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216.
    3. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27:740-756.
    4. Taheri S, et al. Short sleep duration is associated with reduced leptin, elevated ghrelin, and increased BMI. PLoS Med. 2004;1(3):e62.
    5. Wolfe RR. The underappreciated role of muscle in health and disease. Am J Clin Nutr. 2006;84:475-482.
    6. Longland TM, et al. Higher dietary protein during an energy deficit promotes greater lean mass gain and fat loss. Am J Clin Nutr. 2016;103:738-746.
    7. Holst JJ. The physiology of glucagon-like peptide-1. Physiol Rev. 2007;87:1409-1439.
    8. Monami M, et al. Safety issues with GLP-1 receptor agonists (pancreatitis, pancreatic cancer, cholelithiasis). Diabetes Obes Metab. 2017;19(9):1233-1241.
    9. American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. 2023.
    10. Garvey WT, et al. AACE/ACE comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203.


    🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
    Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
    https://www.drmohammedpaika.com

    📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
    Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
    https://www.drmohammedpaika.com/newsletter

    📚 The Weight Equation & The Physician’s Physique
    Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
    https://www.drmohammedpaika.com/books

    👥 Metabolic Health Community
    https://www.skool.com/metabolic-health-community-5316
    👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
    Board-Certified in Internal Medicine and Obesity Medicine
    Certified Personal Trainer & Nutrition Coach
    Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.


    ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
    続きを読む 一部表示
    14 分
  • When Should You Increase or Decrease Your GLP-1 Dose? (Doctor Explains)

    When Should You Increase or Decrease Your GLP-1 Dose? (Doctor Explains)
    2026/09/15
    #GLP1 #Tirzepatide #Semaglutide #WeightLoss #ObesityMedicineShould you increase your GLP-1 dose — or actually decrease it? Before you touch that pen, run through the 7 checks I use with my own patients (and on myself) to decide whether it's time to go up, hold steady, or come down. This isn't about chasing the highest dose on the label — it's about finding the dose you can tolerate and sustain for the long run.I'm Dr. Mohammed Paika — internal medicine physician, board-certified in obesity medicine, and a GLP-1 user myself. In this video I walk through dose duration, your real weight trend, hunger and food noise, tolerability, plateaus vs. real stalls, the rest of your system (protein, sleep, training), and your actual goals — with real hospitalist cases on what happens when dosing goes wrong.🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter📚 The Weight Equation & The Physician’s PhysiquePhysician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.https://www.drmohammedpaika.com/books👥 Metabolic Health Communityhttps://www.skool.com/metabolic-health-community-5316👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKABoard-Certified in Internal Medicine and Obesity MedicineCertified Personal Trainer & Nutrition CoachHelping people understand metabolism, hormones, and sustainable health through evidence-based medicine.TIMESTAMPS0:00 – Intro: should you change your GLP-1 dose?2:12 – How long have you been at this dose?4:00 – What does your real weight trend say?6:36 – Free GLP-1 Diet Cookbook7:13 – What's happening with your hunger?9:05 – How well are you tolerating this dose?11:17 – The GLP-1 Masterclass11:58 – Are you really at a plateau?13:23 – What else changed in your system?14:55 – What are you actually trying to achieve?16:45 – Physician safety reminder17:34 – What's nextReferencesZepbound (tirzepatide) injection, for subcutaneous use. Highlights of Prescribing Information. Eli Lilly and Company. pi.lilly.com/us/zepbound-uspi.pdf; U.S. Food and Drug Administration label, accessdata.fda.gov.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384:989-1002.Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025. PMID: 39996356.Monami M, Nreu B, Scatena A, et al. Safety issues with GLP-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes Obes Metab. 2017;19(9):1233-1241.Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med. 1995;332:621-628.Hall KD. Predicting metabolic adaptation, body weight change, and energy intake in humans. Lancet Diabetes Endocrinol. 2014;2:395-406.Longland TM, Oikawa SY, Mitchell CJ, et al. Higher compared with lower dietary protein during an energy deficit combined with intense exercise promotes greater lean mass gain and fat mass loss. Am J Clin Nutr. 2016;103:738-746.Morton RW, Murphy KT, McKellar SR, et al. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength. Br J Sports Med. 2018;52:376-384.Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity. Am J Clin Nutr. 2025;122:344-367.Garvey WT, Mechanick JI, Brett EM, et al. AACE/ACE comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203.⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
    続きを読む 一部表示
    18 分
  • BPC-157: Everything You Need to Know—Benefits, Risks, & Safety

    BPC-157: Everything You Need to Know—Benefits, Risks, & Safety
    2026/09/12
    #BPC157 #PeptideTherapy #TendonHealing #RegenerativeMedicine #healthscience BPC-157 is everywhere right now — but does the evidence actually justify putting this peptide into your body? In this video, Dr. Mohammed Paika (board-certified internal medicine & obesity medicine) breaks down what BPC-157 actually does, what the animal research shows, what we really know about human safety, and the one theoretical risk that concerns him most as a physician.BPC-157 is not FDA-approved for any human use.🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter📚 The Weight Equation & The Physician’s Physiquehttps://www.drmohammedpaika.com/books👥 Metabolic Health Communityhttps://www.skool.com/metabolic-health-community-5316Timestamps0:00 – Intro: Does the evidence justify this?0:44 – What BPC-157 Actually Is2:19 – How BPC-157 Works (The Mechanism)4:18 – The Musculoskeletal Evidence7:51 – Gut Health10:58 – Brain & Nervous System13:14 – Cardiovascular Health14:07 – The Honest Safety Picture16:20 – What Human Data We Actually Have19:24 – The Risk That Concerns Me Most (Cancer)21:46 – Who Should Actually Consider This24:26 – The Regulatory Reality (FDA, 2026)ReferencesStaresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003;21(6):976-983.Krivic A, et al. Achilles detachment in rat and BPC 157: tendon-to-bone healing. J Orthop Res. 2006;24(5):982-989.Cerovecki T, et al. Pentadecapeptide BPC 157 improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-1161.Staresinic M, et al. Effective therapy of transected quadriceps muscle in rat: BPC 157. J Orthop Res. 2006;24(5):1109-1117.Novinscak T, et al. BPC 157 as effective therapy for muscle crush injury in the rat. Surg Today. 2008;38(8):716-725.Šebečić B, et al. Osteogenic effect of BPC-157 on segmental bone defect healing in rabbits. Bone. 1999;24(3):195-202.Duzel A, et al. BPC 157 in colitis and ischemia/reperfusion in rats. World J Gastroenterol. 2017;23(48):8465-8488.Vuksic T, et al. BPC 157 heals ileoileal anastomosis in the rat. Surg Today. 2007;37(9):768-777.Sikiric P, et al. BPC 157 effects on stomach mucosa integrity and blood pressure. Life Sci. 1994;54(5):PL63-68.Park JM, et al. BPC 157 rescued NSAID-cytotoxicity via intestinal permeability. Curr Pharm Des. 2020;26(25):2971-2981.Tudor M, et al. Traumatic brain injury in mice and BPC 157 effect. Regul Pept. 2010;160(1-3):26-32.Vukojević J, et al. BPC 157 in hippocampal ischemia/reperfusion injuries in rats. Brain Behav. 2020;10(8):e01726.Gjurasin M, et al. Peptide therapy with BPC 157 in traumatic nerve injury. Regul Pept. 2010;160(1-3):33-41.Perovic D, et al. BPC 157 improves healing course of spinal cord injury in rats. J Orthop Surg Res. 2019;14:199.Zemba Cilic A, et al. BPC 157 counteracts catalepsy in rat schizophrenia-like models. Behav Brain Res. 2021;396:112919.Sikiric P, et al. Antidepressant effect of BPC 157 in Porsolt's test and chronic stress in rats. J Physiol Paris. 2000;94(2):99-104.Xu C, et al. Preclinical safety evaluation of BPC-157. Regul Toxicol Pharmacol. 2020;114:104665.He W, et al. Pharmacokinetics of BPC-157 in rats and dogs. Front Pharmacol. 2022;13:1026182.Lee E, et al. Effect of BPC-157 on interstitial cystitis symptoms: a pilot study. Altern Ther Health Med. 2024;30:12-17.Lee E, Burgess C. Safety of IV infusion of BPC-157 in humans: a pilot study. Altern Ther Health Med. 2025.Lee E, Padgett B, et al. Intra-articular BPC 157 for knee pain. Altern Ther Health Med. 2021;27(S1).ClinicalTrials.gov. Study of BPC-157 in healthy volunteers. NCT02637284. Withdrawn.Nair AB, Jacob S. Dose conversion between animals and humans. J Basic Clin Pharm. 2016;7(2):27-31.U.S. FDA. Pharmacy Compounding Advisory Committee vote on BPC-157, July 23, 2026. See also: Pharmaceutical Executive, July 24, 2026.U.S. FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.
    続きを読む 一部表示
    28 分